Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India
Author:
Affiliation:
1. Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
2. Department of pharmacology and toxicology, Bombay College of Pharmacy, Mumbai, Maharashtra, India
Abstract
Publisher
Georg Thieme Verlag KG
Link
http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0043-1777726.pdf
Reference20 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;F Bray;CA Cancer J Clin,2018
2. Treatment of advanced non-small-cell lung cancer: first line, maintenance, and second line– Indian consensus statement update (Under the aegis of Lung Cancer Consortium Asia, Indian Cooperative Oncology Network, Indian Society of Medical and Pediatric Oncology, Molecular Oncology Society, and Association of Physicians of India);K Prabhash;Cancer Res Stat Treat,2021
3. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation- positive non-small cell lung cancer;D Kazandjian;Clin Cancer Res,2016
4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;R Rosell;Lancet Oncol,2012
5. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?;G Recondo;Nat Rev Clin Oncol,2018
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3